Robert W. Baird Has Lowered Expectations for Agenus (NASDAQ:AGEN) Stock Price

Agenus (NASDAQ:AGEN) had its price target lowered by Robert W. Baird from $6.00 to $3.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Robert W. Baird’s target price points to a potential upside of 79.10% from the company’s previous close.

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a report on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.75.

Agenus Trading Down 10.2 %

NASDAQ:AGEN opened at $1.68 on Wednesday. The stock has a market cap of $39.29 million, a P/E ratio of -0.15 and a beta of 1.23. The stock’s 50-day moving average is $3.23 and its 200-day moving average is $3.84. Agenus has a 1-year low of $1.67 and a 1-year high of $19.69.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, topping the consensus estimate of ($2.36) by $0.32. The firm had revenue of $26.84 million for the quarter, compared to the consensus estimate of $30.09 million. As a group, equities analysts forecast that Agenus will post -12.55 EPS for the current year.

Hedge Funds Weigh In On Agenus

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Apollon Wealth Management LLC acquired a new position in shares of Agenus in the fourth quarter worth approximately $55,000. HighTower Advisors LLC lifted its stake in Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 7,530 shares during the period. FMR LLC lifted its stake in Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock valued at $467,000 after buying an additional 27,309 shares during the period. BNP Paribas Financial Markets lifted its stake in Agenus by 2,271.5% in the third quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 37,866 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Agenus by 7.1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock valued at $2,648,000 after buying an additional 32,016 shares during the period. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.